IO Biotech, Inc. reported earnings results for the first quarter ended March 31, 2024. For the first quarter, the company reported net loss was USD 19.46 million compared to USD 17.04 million a year ago. Basic loss per share from continuing operations was USD 0.3 compared to USD 0.59 a year ago.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
1.17 USD | -2.50% | -4.88% | -37.77% |
05-15 | HC Wainwright Adjusts IO Biotech Price Target to $12 From $8, Maintains Buy Rating | MT |
05-14 | IO Biotech, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-37.77% | 79.06M | |
+54.05% | 55.7B | |
+41.08% | 39.91B | |
-5.75% | 39.57B | |
-5.56% | 28.16B | |
+16.35% | 26.3B | |
-20.14% | 18.94B | |
+32.64% | 12.17B | |
+26.96% | 12.12B | |
+2.23% | 12.12B |
- Stock Market
- Equities
- IOBT Stock
- News IO Biotech, Inc.
- IO Biotech, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024